Get started
Author

Wojciech Jurczak

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
2026 · Jeremy S. Abramson, David J. Straus, et al. · Advances in Therapy
PDF
POSTER: ABCL-142: Golcadomide—A Potential First-in-Class Oral CELMoD Combined With Pola-R-CHP in Frontline Aggressive B-Cell Lymphoma: Safety and 12-Month Efficacy
2026 · Muhamad Alhaj Moustafa, Theodoros Vassilakopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-796: Pirtobrutinib in Treatment-Naïve Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Pooled Results From BRUIN CLL-313 and BRUIN CLL-314
2026 · William GWierda, Wojciech Jurczak, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-429: Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor
2026 · Michael Tees, Paolo Ghia, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-427: Updated Efficacy and Safety Data From an Ongoing Phase 1a/b Trial of the Bruton's Tyrosine Kinase Degrader Bexobrutideg (NX-5948) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Across Lines of Therapy
2026 · Zulfa Omer, Talha Munir, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-796: Pirtobrutinib in Treatment-Naïve Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Pooled Results From BRUIN CLL-313 and BRUIN CLL-314
2026 · William G Wierda, Wojciech Jurczak, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-429: Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor
2026 · Michael Tees, Paolo Ghia, et al. · Clinical Lymphoma Myeloma & Leukemia
ABCL-142: Golcadomide—A Potential First-in-Class Oral CELMoD Combined With Pola-R-CHP in Frontline Aggressive B-Cell Lymphoma: Safety and 12-Month Efficacy
2026 · Muhamad Alhaj Moustafa, Theodoros Vassilakopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-427: Updated Efficacy and Safety Data From an Ongoing Phase 1a/b Trial of the Bruton's Tyrosine Kinase Degrader Bexobrutideg (NX-5948) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Across Lines of Therapy
2026 · Zulfa Omer, Talha Munir, et al. · Clinical Lymphoma Myeloma & Leukemia
Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary
2026 · Jeremy S. Abramson, David J. Straus, et al. · Figshare
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results.
2026 · Marc S. Hoffmann, Grzegorz S. Nowakowski, et al. · Journal of Clinical Oncology
Works count: 11
Citation count:
H-index:
I10-index:
Year
Topic
Type